Investor Relations

The Board

Home>Corporate Governance>The Board

Han Yuewei - Chairman and Non-executive Director

Mr. Han Yuewei, currently serves as a Vice General Manager of China Resources (Holdings) Company Limited (“CR Holdings”). Mr. Han was appointed as an executive director and chief executive officer of the Company in October 2019 and was appointed as the chairman of the board of the Company in December 2021. Mr. Han ceased to be the chief executive officer and was re-designated as a non-executive director and continued to serve as the chairman of the board in January 2022. Mr. Han served as a director of China Resources Sanjiu Medical & Pharmaceutical Company Limited （華潤三九醫藥股份有限公司）(“CR Sanjiu”) (the shares of which are listed on Shenzhen Stock Exchange, stock code: 000999) from December 2019 to February 2022, a director of China Resources Double-Crane Pharmaceutical Company Limited （華潤雙鶴藥業股份有限公司）(“CR Double-Crane”) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600062) from December 2019 to February 2022, the chairman and a director of Dong-E-E-Jiao Company Limited （東阿阿膠股份有限公司）(“Dong-E-E-Jiao”) (the shares of which are listed on the Shenzhen Stock Exchange, stock code: 000423) from December 2019 to January 2022 and an executive director of China Resources Medical Holdings Company Limited (“CR Medical”) (the shares of which are listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), stock code: 1515) from October 2017 to October 2019, during which he served as the chief executive officer of CR Medical and the general manager of China Resources Healthcare Group Limited, the controlling shareholder of CR Medical. Mr. Han worked for China Resources Land Limited (“CR Land”) (the shares of which are listed on the Stock Exchange, stock code: 1109) from October 2010 to October 2017, during which he served as deputy general manager of Shenyang Region, deputy general manager of Shenzhen Region, director of engineering and vice president of CR Land. Prior to joining CR Land, Mr. Han worked as the deputy director and director of the Bureau of Public Works of Shenzhen Municipality（深圳市建築工務署）from April 2002 to October 2010. Mr. Han obtained a master’s degree in Construction Economics and Management from Tsinghua University（清華大學）and a bachelor’s degree in Construction Management from Tsinghua University in July 1993 and July 1991 respectively.

Bai Xiaosong - Executive Director and Chief Executive Officer

Mr. Bai Xiaosong, was appointed as an executive director and chief executive officer of the Company in January 2022. Mr. Bai currently serves as a director of CR Sanjiu and CR Double-Crane. He served as a vice president of CR Sanjiu from June 2021 to December 2021, an assistant general manager of China Resources Snow Breweries (China) Co., Ltd.（華潤雪花啤酒（中國）有限公司） (“CR Snow Breweries”) from March 2016 to October 2018 and served as a deputy general manager of CR Snow Breweries from October 2018 to June 2021. He also served as an associate president of CR Double-Crane, a human resources and development controller and a deputy general manager of China Resources Shenyang Sanyo Compressor Co., Ltd.（沈陽華潤三洋壓縮機有限公司）, a senior analyst and a sales director of CR Holdings. Mr. Bai holds a bachelor’s degree in Engineering (Petroleum Processing) from Fushun Petroleum Institute, Department of Petrochemical Engineering and a master’s degree of Economics in Finance from Peking University, School of Economics.

Tao Ran - Executive Director and Vice President

Mr. Tao Ran, was appointed as the vice president of the Company in June 2021 and appointed as an executive Director in September 2021. He is concurrently a director of China Resources Jiangzhong Pharmaceutical Group Co., Ltd., a director of China Resources Zizhu Pharmaceutical Co., Ltd, a director of China Resources Pharmaceutical Commercial Group Company Limited, a chairman of the supervisory board of CR Sanjiu, a supervisor of CR Double-Crane, a chairman of the supervisory board of Dong-E-E-Jiao. Mr. Tao was appointed as a non-executive director of Immunotech Biopharm Ltd (the shares of which are listed on the Stock Exchange, stock code: 6978) in August 2021 and the chairman and director of Boya Bio-pharmaceutical Group Co. Ltd.（博雅生物制药集团股份有限公司）(the shares of which are listed on the Shenzhen Stock Exchange, Stock Code: 300294) in December 2021. Mr. Tao has been a deputy chief of Import Division I of China Resources National Corporation (currently known as China Resources Company Limited), a senior manager of Investment Division and a deputy general manager of China Resources Textiles (Holdings) Co., Ltd. and a senior director of Strategic Development Division and the general manager of Strategic Development Division of CR Pharmaceutical. Mr. Tao holds a bachelor’s degree in Engineering awarded by Shanghai Jiao Tong University, China and a master’s degree in Economics awarded by Beihang University, China.

Weng Jingwen - Executive Director, Chief Financial Officer and Vice President

Mdm. Weng Jingwen was appointed as an executive Director, chief financial officer and vice president of the Company in July 2019, has many years of experience in financial management, auditing, strategic development and business analysis. Mdm. Weng also serves as a director of Dong-E-E-Jiao and a supervisor of CR Sanjiu etc. served as a director of CR Double-Crane from December 2015 to September 2022. Mdm. Weng served as a general manager of internal audit department and strategic controller of China Resources Gas Group Limited (listed on the Stock Exchange, stock code: 1193), deputy strategic development controller of CR Holdings (with a focus in pharmaceutical and healthcare areas). Mdm. Weng was previously engaged in financial management and auditing job in the International Business Machines Corporation and PricewaterhouseCoopers before joining China Resources Group. Mdm. Weng obtained a bachelor’s degree in economics from Zhejiang University, China and an MBA degree from the Hong Kong University of Science and Technology.

Lin Guolong - Non-executive Director

Mr. Lin Guolong, was appointed as a non-executive Director in September 2021, has been a designated external director of the business unit of CR Holdings since August 2021 and has been a designated external director of China Resources Capital Holdings Company Limited since November 2021. Mr. Lin had been a deputy general manager of the finance department of CR Holdings from August 2004 to August 2011 and from July 2018 to August 2021. From August 2011 to July 2018, he was vice president and chief financial officer of CR Sanjiu. Mr. Lin holds a bachelor’s degree in Economics from the Accounting Department of Xiamen University and a Master of Business Administration degree from the University of South Australia.

Hou Bo - Non-executive Director

Mr. Hou Bo, was appointed as a non-executive Director on March 2021 and joined the Beijing State-owned Capital Operation and Management Company Limited (“BSCOMC”) in 2019 and is currently an external task director of the BSCOMC. Mr. Hou has many years of experience in financial management. He served as the director of the insurance and non-banking services department of the Beijing Municipal Bureau of Financial Work（北京市金融工作局）, the director of the financial market department of the Beijing Municipal Bureau of Financial Work（北京市金融工作局）, the deputy general manager (deputy bureau level) of the former Beijing Equity Exchange Center Co., Ltd.（北京股權交易中心有限公司）, and deputy general manager of Zhongguancun Equity Exchange Service Group Co., Ltd.（中關村股權交易服務集團有限公司）. Mr. Hou graduated from the Department of Mechanical Engineering of Tsinghua University in 1986 with a bachelor of Engineering degree in Forging and Pressing. He graduated from the Department of Business and Economics of Capital University of Economics and Business with a master degree in Foreign Trade Operations and Management in 1997 and obtained a doctor of Engineering degree in Resources Industry Economics from the school of Earth Sciences and Resources of the China University of Geosciences, Beijing in 2009. He is also a senior international business engineer.

Jiao Ruifang - Non-executive Director

Mdm. Jiao Ruifang was appointed as a non-executive Director in January 2022. Mdm. Jiao joined the BSCOMC in 2014 and currently the general manager of the capital operation department of the BSCOMC and a non-independent director of Beijing Urban-Rural Commercial (Group) Co., Ltd.（北京城鄉商業（集團）股份有限公司） (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600861). Mdm. Jiao was appointed as a director of Hainan Jingliang Holdings Co., Ltd.（海南京粮控股股份有限公司）(the shares of which are listed on Shenzhen Stock Exchange, stock code: 000505 and 200505) in March 2022 and Beiqi Foton Motor Co., Ltd. (北汽福田汽車股份有限公司) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600166) in January 2022. Mdm. Jiao served as the board secretary of Beiren Printing Machinery Holdings Limited（北人印刷機械股份有限公司）, the board secretary of Beijing Jingcheng Machinery Machinery Electric Company Limited（北京京城機電股份有限公司）and the deputy general manager of Beijing Tianhai Industrial Co., Ltd.（北京天海工業有限公司）. Mdm. Jiao holds an MBA in Finance from The Chinese University of Hong Kong-Tsinghua University.

Shing Mo Han Yvonne - Independent Non-executive Director

Mdm. Shing Mo Han Yvonne, BBS, JP, was appointed as an independent non-executive Director in August 2017. Mdm. Shing was appointed as a Justice of Peace of the HKSAR in 2013 and awarded Bronze Bauhinia Star in 2017. Mdm. Shing is currently the chairman of Yinn Advisory Services Limited and an independent non-executive director of CSSC (Hong Kong) Shipping Company Limited (the shares of which are listed on the Stock Exchange, stock code: 3877), AEON Credit Service (Asia) Company Limited (the shares of which are listed on the Stock Exchange, stock code: 900), Sirnaomics Ltd. (the shares of which are listed on the Stock Exchange, stock code: 2257) and an independent director of China Merchants Energy Shipping Company Limited (the shares of which are listed on Shanghai Stock Exchange, stock code: 601872). Mdm. Shing was a partner of Deloitte China for over 26 years until her retirement in May 2016. She is also a member of the 10th, 11th and 12th Jiangsu Provincial Committee of the CPPCC. Mdm. Shing is a founding member and past president of the Association of Women Accountants (Hong Kong) and the former chairman of Hong Kong Institute of Certified Public Accountants Taxation Committee. Her professional qualifications include fellow member of the Hong Kong Institute of Certified Public Accountants, Association of Chartered Certified Accountants and Corporate Governance Institute. Mdm. Shing’s current public appointments include court member of the Hong Kong Polytechnic University, and advisor and member of the Finance Committee of Our Hong Kong Foundation. In 2006, Mdm. Shing received the National Hundred Outstanding Women Entrepreneurs Award in Great Hall of the People in Beijing. She also received the Outstanding Alumni Award of Hong Kong Polytechnic University in 2007. Mdm. Shing has been consecutively named from 2001 to 2015 in International Tax Review as one of the World’s Leading Tax Advisors in Hong Kong and Mainland. Mdm. Shing graduated from the Hong Kong Polytechnic (currently known as the Hong Kong Polytechnic University) and obtained a Higher Diploma in Accountancy and was awarded in 2016/2017 Honorary University Fellow of the Hong Kong Polytechnic University.

Kwok Kin Fun - Independent Non-executive Director

Mr. Kwok Kin Fun, BBS, JP, was appointed as an independent non-executive Director in June 2016. Mr. Kwok also serves as an executive committee member of Rehabilitation International and global vice chairman of Social Commission of Rehabilitation International, the co-chair of the Conference Organizing Committee of Rehabilitation International Asia & Pacific Regional Conference 2019, the chairman of Incheon Strategy Group Committee of Asia and Pacific Disability Forum, a vice chairman of The Hong Kong Joint Council for People with Disabilities, a vice chairman of The Hong Kong Society for Rehabilitation, a council member of Fu Hong Society, a member of Hospital Authority Central Institutional Review Board (1 April 2021 to 31 March 2024), a member of Voting Members Committee of Riding For the Disabled Association, the chairman of Accessible IT Development Association Limited, a professional committee consultant to the Disabled Research and Professional Committee of the China Association of Rehabilitation of Disabled Persons (March 2019-March 2023), a professional consultant to the Professional Committee of Shenzhen Smart Assistive Tech Association, and an off-campus co-operative instructor to PHD students in the field of athletic rehabilitation in the Sports Institute of Soochow University (2019–2022). Mr. Kwok has over 30 years of experience in disability research and medical research ethics. He successively served as a senior lecturer, a principal lecturer, a university senior lecturer and an associate professor of the City University of Hong Kong from 1985 to 2009, and after retirement served as full-time and part-time senior research fellow. Mr. Kwok was appointed as a Justice of the Peace by the government of Hong Kong in 1997 and received the Bronze Bauhinia Star awarded by the government of Hong Kong SAR in 2005, “Kazuo Itoga” Memorial Prize awarded by the government of Shiga Prefecture, Japan in 2006, and the Promoter title of “Asian and Pacific Decade of Persons with Disabilities, 2013– 2022” awarded by United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP) in 2012. Mr. Kwok holds a bachelor’s degree in social science from the University of Hong Kong, a master’s degree in social science from the Chinese University of Hong Kong, and a Ph.D. degree in philosophy from the University of Nottingham, the United Kingdom.<BR style=" clear=all></SPAN></P></DIV></div></body></html>

Fu Tingmei - Independent Non-executive Director

Mr. Fu Tingmei, was appointed as an independent non-executive Director in June 2016. Mr. Fu has over 20 years of experience in investment, finance, law and business management. Mr. Fu currently serves as an independent non-executive director of Guotai Junan International Holdings Limited (the shares of which are listed on the Stock Exchange, stock code: 1788), Postal Savings Bank of China Co., Ltd. (the shares of which are listed on the Stock Exchange, stock code: 1658) and COFCO Joycome Foods Limited (formerly known as: “COFCO Meat Holdings Limited”) (the shares of which are listed on the Stock Exchange, stock code: 1610). Mr. Fu was an independent non-executive director of Beijing Enterprises Holdings Limited (the shares of which are listed on the Stock Exchange, stock code: 0392) from July 2008 to June 2017 and an independent non-executive director of CPMC Holdings Limited (the shares of which are listed on the Stock Exchange, stock code: 0906) from June 2008 to July 2019. Mr. Fu holds a master’s degree in law and a Ph.D. degree in law from London University, the United Kingdom.

Zhang Kejian - Independent Non-executive Director

Mr. Zhang Kejian, was appointed as an independent non-executive Director in June 2016. Mr. Zhang also serves as an independent director of Zhejiang Hisoar Pharmaceutical Co. Ltd.（浙江海翔药业股份有限公司）(the shares of which are listed on Shenzhen Stock Exchange, stock code: 002099), and non-independent director of Guangzhou Boji Medical Biotechnological Co.,Ltd.（广州博济医药生物技术股份有限公司）(the shares of which are listed on Shenzhen Stock Exchange GEM, stock code: 300404), an independent director of Liaoning Chengda Biotechnology Co.,Ltd.（辽宁成大生物股份有限公司）(the shares of which are listed on the Shanghai Stock Exchange in October 2021, stock code: 688739) and the Chief Scientist of The South China Center for Innovative Pharmaceuticals（广东华南新药创制中心）. Mr. Zhang has over 20 years of experience in the pharmaceutical industry of PRC. He was an independent director of CR Double-Crane from February 2016 to June 2018, an independent director of Yifan Pharmaceutical Co., Ltd.（亿帆药业股份有限公司）(the shares of which are listed on Shenzhen Stock Exchange, stock code: 002019) from October 2014 to November 2020 and an independent director of Hunan Fangsheng Pharmaceutical Co., Ltd（湖南方盛制药股份有限公司）(the shares of which are listed on Shanghai Stock Exchange, stock code: 603998) from October 2018 to January 2021. He was employed as a professor of School of Pharmaceutical Sciences of Sun Yat-sen University and the director (Pharmacy Administration) of The South China Center for Innovative Pharmaceuticals, a researcher at the Institute of Medicine, Chinese Academy of Medical Sciences（中国医学科学院药物研究所）, and successively served as a deputy director of Pharmaceutical Evaluation Center（药品审评中心）and a deputy director of Medical Device Evaluation Center（医疗器械技术审评中心）under the State Food and Drug Administration of the PRC（国家食品药品监督管理局）. Mr. Zhang received a master’s degree in pathophysiology from China Medical University in Shenyang, the PRC and a doctor’s degree in pharmacy from the School of Pharmaceutical Sciences of Chiba University in Chiba, Japan.